Efficacy and Safety of Novel Aspirin Formulations: A Randomized, Double-Blind, Placebo-Controlled Study

Low-dose aspirin represents the best option in the secondary prevention of coronary artery disease, but its extensive use in primary prevention is limited by the occurrence of gastric mucosal lesions and increased risk of bleeding. We investigated the safety profile of a novel sublingual aspirin for...

Descripción completa

Detalles Bibliográficos
Autores principales: Mollace, Rocco, Gliozzi, Micaela, Macrì, Roberta, Tavernese, Annamaria, Musolino, Vincenzo, Carresi, Cristina, Maiuolo, Jessica, Muscoli, Carolina, Tomino, Carlo, Rosano, Giuseppe Maria, Fini, Massimo, Volterrani, Maurizio, Silvestrini, Bruno, Mollace, Vincenzo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8779026/
https://www.ncbi.nlm.nih.gov/pubmed/35057084
http://dx.doi.org/10.3390/pharmaceutics14010187

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8779026/
https://www.ncbi.nlm.nih.gov/pubmed/35057084
http://dx.doi.org/10.3390/pharmaceutics14010187

Ejemplares similares